Anti-Aging Therapeutics Volume XVI

A4M American Academy

Description

Proceedings of the Twenty-First World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies, sponsored by the American Academy of Anti-Aging Medicine (A4M)

Sujets

• Medical
• Médecine
• Clinical Medicine

Informations

• Publié par: eBookIt.com
• Date de parution: 13 mars 2015
• Nombre de lectures: 0
• EAN13: 9781934715178
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Anti-Aging Therapeutics
Volume XVI
2013 Conference Year
 
Editors
Dr. Ronald Klatz
and
Dr. Robert Goldman
 

An official educational work published by A4M Publications
1510 West Montana Street
Chicago, IL 60614 USA
TEL: [phone] | WEBSITE: www.worldhealth.net
 
Visit
The World Health Network, at www.worldhealth.net ,
leading Internet resource for non-commercial health information;
and
The A4M’s Special Information Center, at www.a4minfo.net , the A4M’s Publishing and Media Showcase

IMPORTANT – PLEASE READ
 
The content presented in the Anti-Aging Therapeutics, volume 16 is for educational purposes only and is specifically designed for those with a health, medical, or biotechnological education or professional experience. Anti-Aging Therapeutics, volume 16 does not prevent, diagnose, treat or cure disease or illness.
While potentially therapeutic pharmaceuticals, nutraceuticals (dietary supplementation) and interventive therapies are described in the A4M's Anti-Aging Therapeutics, volume 16 , this work serves the sole purpose of functioning as an informational resource. Under no circumstances is the reader to construe endorsement by A4M of any specific companies or products. Quite to the contrary, Caveat Emptor. It is the reader's responsibility to investigate the product, the vendor, and the product information.
Dosing of nutraceuticals can be highly variable. Proper dosing is based on parameters including sex, age, and whether the patient is well or ill (and, if ill, whether it is a chronic or acute situation). Additionally, efficiency of absorption of a particular type of product and the quality of its individual ingredients are two major considerations for choosing appropriate specific agents for an individual's medical situation.
Furthermore, anyone with malignancy should consult their physician or oncologist prior to beginning, or continuing, any hormone therapy program.
Finally, please be mindful that just because a product is natural doesn't mean it's safe for everyone. A small portion of the general population may react adversely to components in nutraceuticals (especially herbal products). A complete inventory of interventions utilized by a patient should be maintained by physicians and health practitioners dispensing anti-aging medical care.
Anti-Aging Therapeutics, volume 16 is, again, designed for those with a health, medical, or biotechnological education or professional experience. It is not intended to provide medical advice, and is not to be used as a substitute for advice from a physician or health practitioner. If you are a consumer interested in any of the approaches discussed in these chapters, it is absolutely essential that you have a thorough discussion with your physician to understand all benefits and risks.
For those individuals interested in the diagnostics and/or therapies described by chapter authors of Anti-Aging Therapeutics, volume 16 , A4M urges that you consult a knowledgeable physician or health practitioner, preferably one who has been Board Certified in Anti-Aging Medicine. You may find one by utilizing the Anti-Aging Directory at www.a4m.com .
 
 
Anti-Aging Therapeutics volume 16
Copyright © 2015. American Academy of Anti-Aging Medicine.
1510 West Montana Street; Chicago IL 60614 USA.
All rights reserved.
 
Published in eBook format by A4M American Academy of Anti-Aging Medicine
Converted by http://www.eBookIt.com
 
ISBN-13: 978-1-9347-1517-8
 
Electronic and/or print reproduction, storage in an electronic and/or physical retrieval system, or transmission by any means (electronic, mechanical, photocopying, microfilming, recording, or otherwise) requires the advance written consent by the publisher.
Chapter 1
Developments in Human Longevity: A State-of-the-Specialty Report
Ronald Klatz, M.D., D.O., President
Robert Goldman, M.D., Ph.D., D.O., FAASP, Chairman
The American Academy of Anti-Aging Medicine (A4M; www.worldhealth.net )
 
Introduction
Thousands of physicians and practitioners in private medical offices, as well as at some of the most prestigious teaching hospitals around the world, now embrace the anti-aging medical model. Undeniably, anti-aging medicine is achieving demonstrable and objective results that beneficially impact the degenerative diseases of aging. Anti-aging medicine is transforming healthcare, one practice at a time.
 
Demographics of Aging
As of this writing, Monaco leads the world in life expectancy at-birth, standing at 89.57 years. Macau follows at 84.48 years, then Japan at 84.46 years, Singapore at 84.38 years, and San Marino rounds out the top-five at 83.18 years. 1
A number of nations report sharply rising life expectancy data:
• The United States Centers for Disease Control & Prevention (CDC) reports 2 that the average life expectancy in the US rose to 78.8 years in 2012. The age-adjusted death rate for Americans decreased 1.1%, as seniors’ life expectancy rose to stand at an additional 19.3 years. Women age 65 and older in 2012 can expect to live another 20.5 years, while men may get around an additional 18 years. The CDC Data Brief attributes the increased life expectancy to an overall greater awareness and implementation of healthy lifestyles.
• The United Kingdom’s Office for National Statistics reports 3 that as many as two-thirds of the babies born in the UK in 2012 will celebrate their100th birthday. And by 2037, most British children will routinely live until nearly 100 years of age.
• The lifespan for Swedish women 4 has risen 15 minutes each hour since 1840. While a Swedish female born in 1840 lived to be just 45 years, a girl born in 2013 will live to an average of 84 years – a gain of 40 years in six generations.
Researchers from the Max Planck Institute for Demographic Research (Germany) report 5 that: “Life expectancy is increasing in most countries and has exceeded 80 in several, as low-mortality nations continue to make progress in averting deaths.” Observing a sharp decline in early mortality in the past four generations that points to “the bulk of this mortality reduction has occurred since 1900,” the study authors cite improvements in clean water, shelter, food, and medicine as primary factors in the life expectancy gains. The study authors note that: “This observed plasticity in age-specific risk of death is at odds with conventional theories of aging.”
 
The Anti-Aging Medical Model
The goal of anti-aging medicine is not to merely prolong the total years of an individual's life, but to ensure that those years are enjoyed in a productive and vital fashion. The clinical specialty of anti-aging medicine utilizes diagnostic protocols that are supported by scientific evidence to arrive at an objective assessment upon which effective treatment is assigned. Physicians who dispense anti-aging medical care are concerned with the restoration of optimal functioning of the human body’s systems, organs, tissues, and cells.
People may lose 30 minutes of life expectancy for every two cigarettes they smoke, for being 11 pounds overweight, and for eating an extra portion of red meat daily. David Spiegelhalter 6 , from the University of Cambridge, has coined the concept of a “microlife," defined as 30 minutes of life expectancy – as a practical substitution for the statistical concept of the hazard ratio. He computed that a million half hours -- or 57 years -- roughly corresponds to a lifetime of adult exposure to any given hazard. Further, he noted that at current mortality rates in the UK, a 35-year-old can expect to live another 55 years or 481,000 hours or very nearly a million microlives. Spiegelhalter has calculated that people may lose 30 minutes of life expectancy for every two cigarettes they smoke, for being 11 pounds overweight, and for eating an extra portion of red meat daily. Dr Spiegelhalter submits that this approach "allows a general, non-academic audience to make rough but fair comparisons between the sizes of chronic risks, and is based on a metaphor of 'speed of ageing.'
Potentially 37 million premature deaths over 15 years may be prevented, simply if people modulated six specific modifiable risk factors. Various countries aim to reduce premature mortality from four main non-communicable diseases (NCDs)-namely – cardiovascular diseases, chronic respiratory diseases, cancers, and diabetes. These nations have targeted to reduce these disease incidences by 25% from 2010 levels by 2025. Potentially 37 million premature deaths over 15 years may be prevented, simply if nations adopt the anti-aging medical model. Majid Ezzati 7 from Imperial College London (United Kingdom), and colleagues report that this target may be achievable by the reduction of six specific modifiable risk factors. Using country-level data on deaths and risk factors and epidemiological models, the researchers estimate the number of deaths that could be prevented between 2010 and 2025 by reducing the burden of each of the six risk factors to globally-agreed target levels -- tobacco use (30% reduction and a more ambitious 50% reduction), alcohol use (10% reduction), salt intake (30% reduction), high blood pressure (25% reduction), and halting the rise in the prevalence of obesity and diabetes. Overall, the findings suggest that meeting the targets for all six risk factors would reduce the risk of dying prematurely from the four main NCDs by 22% in men and 19% for women in 2025 compared to what they were in 2010. Worldwide, this improvement is equivalent to delaying or preventing at least 16 million deaths in people aged 30-70 years and 21 million in those aged 70 years or older over 15 years. The authors predict that the largest benefits will come from reducing high blood pressure and tobacco use. They calculate that a more ambitious 50% reduction in prevalence of smoking by 2025, rather than the current target of 30%, would reduce the risk of dying prematurely by more than 2